AIM-HI Accelerator Fund shared a post on LinkedIn:
“AIM-HI portfolio company Yiviva reports promising Phase 2b results!
At ASCO25 and ESMOGI25, Yiviva presented new data showing that YIV-906, when combined with sorafenib, significantly improves survival and tolerability for patients with advanced hepatocellular carcinoma and chronic hepatitis B.
Key findings:
- Median overall survival nearly doubled
- Improved tumor progression timelines
- Better treatment tolerance
Backed by AIM-HI, NFCR, AFCR, and Yale, Yiviva is redefining cancer treatment by merging systems biology with centuries-old medicinal knowledge.
More posts featuring AIM-HI Accelerator Fund.